**S1 Table.** Concentrations of cerebral biomarkers and association with preeclampsia

|                | OR (95% CI)     | aOR\(^1\) (95% CI) | aOR\(^2\) (95% CI) |
|----------------|-----------------|---------------------|---------------------|
| **CSF**        |                 |                     |                     |
| S100B (ug/L)   | 0.36 (0.26-5.01)| 0.25 (0.01-4.46)    | 0.40 (0.02-10.72)   |
| NSE (ug/L)     | 0.72 (0.50-1.02)| 0.77 (0.55-1.08)    | 0.66 (0.39-1.12)    |
| tau (pg/ml)    | 0.99 (0.98-1.00)| 0.99 (0.98-1.00)    | 0.99 (0.98-1.01)    |
| NfL (pg/ml)    | 1.01 (1.01-1.03)| 1.02 (1.00-1.04)    | 1.01 (1.00-2.02)    |
| **Circulating concentrations** | |                     |                     |
| S100B (ug/L)*  | 3.84 (1.07-13.87)| 3.62 (0.98-13.38)   | 1.74 (0.42-7.19)    |
| tau (pg/ml)    | 1.02 (0.96-1.08)| 1.02 (0.95-1.09)    | 0.98 (0.76-1.25)    |
| NfL (pg/ml)    | 1.64 (1.09-2.48)| 1.70 (1.04-2.78)    | 1.78 (1.05-3.02)    |
| Albumin ratio  | 1.30 (0.80-2.11)| 1.86 (0.87-3.96)    | 1.21 (0.77-1.90)    |

Logistic regression analysis with odds ratios for likelihood of preeclampsia. S100B was measured in serum. The remaining biomarkers were measured in plasma.

\(^1\)Adjusted for parity

\(^2\)Adjusted for body mass index

CSF: cerebrospinal fluid; OR, odds ratio; CI, confidence interval; aOR, adjusted odds ratio; NSE, neuron-specific enolase; NfL, Neurofilament Light Chain

*For an inter-quartile range increase